Galderma has received FDA approval for Restylane Contour for correction of temple hollowing—a targeted indication that positions the product as a direct competitor to AbbVie's Voluma XC and Revance's RHA 4 in the structural volumization space. Temple hollowing is a visible sign of age-related volume loss and a frequent patient complaint; practices that perform mid-face and temple augmentation can justify stocking a dedicated filler for this anatomy.
Injectables
Galderma Wins FDA Clearance for Restylane Contour — Temple Hollowing Now Indicated
Galderma's new temple indication for Restylane Contour directly competes with Allergan's Voluma and RHA for facial architecture.
Temple hollowing is a visible sign of age-related volume loss and a frequent patient complaint.
Restylane Contour is a thicker, more cohesive HA formulation than Restylane Lyft, designed for deeper placement and structural support. The temple indication is strategically important because it's a lower-risk, high-visibility treatment that builds patient confidence in a practice's aesthetic eye. For practices already using Restylane, this approval removes friction to upselling temple work and reduces the need to switch to competitor products for that specific indication.
Source: original report ↗
Frequently asked questions
What is Restylane Contour FDA approved for now?
Restylane Contour has received FDA approval for correction of temple hollowing, a visible sign of age-related volume loss. This new indication positions it as a direct competitor to Voluma XC and RHA 4 for structural volumization in the mid-face and temple area.
How is Restylane Contour different from Restylane Lyft?
Restylane Contour is a thicker, more cohesive HA formulation designed for deeper placement and structural support, whereas Restylane Lyft has a different consistency profile. Contour's formulation makes it better suited for temple hollowing and facial architecture correction.
Why should medspa practices stock Restylane Contour for temples?
Temple hollowing correction is a lower-risk, high-visibility treatment that builds patient confidence in a practice's aesthetic expertise. For practices already using Restylane, this approval removes the need to switch to competitor products like Voluma for temple work and creates an upsell opportunity for mid-face augmentation.
What competitors does Restylane Contour temple indication target?
The new temple indication directly competes with AbbVie's Voluma XC and Revance's RHA 4, both established products in the structural volumization space. This approval gives Galderma a dedicated offering in a high-demand treatment area.
Is temple hollowing a common patient concern?
Yes, temple hollowing is a frequent patient complaint and a visible sign of age-related volume loss. It's a common area for mid-face and temple augmentation, making it a valuable treatment offering for aesthetic practices.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.